

Study Number: MOG11042
Test Type: MOG - Range Finding
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate
CAS Number: 115-86-6

Date Report Requested: 02/17/2021
Time Report Requested: 13:07:50
Lab: Battelle

Study Number: MOG11042
Study Gender: Both
PWG Approval Date: See web page for date of PWG Approval
Version: v1.1.7

Study Number: MOG11042

Test Type: MOG - Range Finding

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Triphenyl Phosphate

CAS Number: 115-86-6

Date Report Requested: 02/17/2021

Time Report Requested: 13:07:50

Lab: Battelle

F0 Female

		Treatment Groups (ppm)				
	Phase Day	0	1000	3000	10000	15000
Blood Acetylcholinesterase (U/mL)	LD 28	0.28 ± 0.05 (10) **	0.26 ± 0.03 (10)	0.16 ± 0.02 (10) *	0.06 ± 0.00 (10) **	0.04 ± 0.00 (8) **
Percent of Control			93.9	57.0	21.7	13.1
Blood Butylcholinesterase (U/mL)	LD 28	0.09 ± 0.02 (10) **	0.07 ± 0.01 (10)	0.04 ± 0.01 (10) *	0.01 ± 0.00 (10) **	0.01 ± 0.00 (8) **
Percent of Control			79.3	41.4	13.8	12.9

Study Number: MOG11042

Test Type: MOG - Range Finding

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Triphenyl Phosphate

CAS Number: 115-86-6

Date Report Requested: 02/17/2021

Time Report Requested: 13:07:50

Lab: Battelle

F1 Male

	Phase Day	Treatment Groups (ppm)				
		0	1000	3000	10000	15000
Blood Acetylcholinesterase (U/mL) Percent of Control	PND 28	0.20 ± 0.04 (8) **	0.28 ± 0.05 (8) 142.3	0.19 ± 0.02 (7) 97.4	0.12 ± 0.00 (8) 62.8	0.11 ± 0.01 (7) 57.9
Brain Acetylcholinesterase (U/g) Percent of Control	PND 28	2.14 ± 0.13 (8) **	1.70 ± 0.10 (8) * 79.5	1.63 ± 0.13 (7) * 76.2	1.01 ± 0.08 (8) ** 47.0	0.86 ± 0.06 (8) ** 40.2
Blood Butylcholinesterase (U/mL) Percent of Control	PND 28	0.05 ± 0.01 (8) **	0.09 ± 0.02 (8) 168.3	0.05 ± 0.01 (7) 97.6	0.03 ± 0.00 (8) 51.2	0.02 ± 0.00 (7) * 41.8
Brain ButylCholinesterase (U/g) Percent of Control	PND 28	1.52 ± 0.09 (8) **	1.33 ± 0.09 (8) 87.4	1.14 ± 0.07 (7) ** 74.7	0.77 ± 0.05 (8) ** 50.2	0.68 ± 0.06 (8) ** 45.0

Study Number: MOG11042

Test Type: MOG - Range Finding

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Triphenyl Phosphate

CAS Number: 115-86-6

Date Report Requested: 02/17/2021

Time Report Requested: 13:07:50

Lab: Battelle

F1 Female

	Phase Day	Treatment Groups (ppm)				
		0	1000	3000	10000	15000
Blood Acetylcholinesterase (U/mL) Percent of Control	PND 28	0.18 ± 0.02 (8) **	0.23 ± 0.04 (8) 130.5	0.19 ± 0.03 (7) 110.2	0.13 ± 0.01 (8) 74.5	0.12 ± 0.01 (8) 66.7
Brain Acetylcholinesterase (U/g) Percent of Control	PND 28	1.73 ± 0.05 (8) **	1.79 ± 0.10 (8) 103.5	1.44 ± 0.12 (7) 83.1	1.12 ± 0.10 (8) ** 64.6	0.97 ± 0.08 (8) ** 55.7
Blood Butylcholinesterase (U/mL) Percent of Control	PND 28	0.04 ± 0.01 (8) **	0.07 ± 0.02 (8) 148.6	0.06 ± 0.01 (7) 127.3	0.03 ± 0.00 (8) 60.0	0.02 ± 0.00 (8) * 45.7
Brain ButylCholinesterase (U/g) Percent of Control	PND 28	1.27 ± 0.06 (8) **	1.42 ± 0.08 (8) 111.9	0.96 ± 0.07 (7) * 75.9	0.80 ± 0.07 (8) ** 63.2	0.75 ± 0.05 (8) ** 58.8

Study Number: MOG11042

Test Type: MOG - Range Finding

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Triphenyl Phosphate

CAS Number: 115-86-6

Date Report Requested: 02/17/2021

Time Report Requested: 13:07:50

Lab: Battelle

LEGEND

Values given as mean \pm SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100

LD – Lactation Day; PND – Postnatal Day, adults post-weaning

Statistical analysis were performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

The 30,000 ppm group was terminated due to excessive toxicity on GD12. Measurements taken from this dose group were excluded from the analysis.

**** END OF REPORT ****